ASH 2024 CLL Highlights

0:01:02

Highlights in CLL from ASH 2024

0:22:00

ASH 2024 CLL Highlights - SEQUOIA, AMPLIFY, CELESTIAL

0:00:47

CLL highlights from ASH: the Phase III AMPLIFY trial

0:57:56

ASH 2024 Lymphoma and CLL Highlights

1:05:30

Highlights from the ASH 2024 Annual Meeting: B-Cell Lymphoma | Lymphoma Research Foundation Webinars

0:51:21

Highlights from Attending ASH 2024

0:18:06

ASH Lymphoma 2024 Highlights - POLARIX Update, inMIND, TRIANGLE, ENRICH with Dr. Pallawi Torka

0:02:30

Top AML highlights from ASH 2024: menin inhibitors & gilteritinib versus midostaurin in induction

0:02:26

Practice-changing updates in CLL from ASH 2024: findings from the AMPLIFY trial

0:10:44

Top NHL highlights from ASH 2024 & trials to look out for in 2025: expert insights

0:04:13

Top AML highlights from ASH 2024: what community oncologists should know

1:00:45

ASH 2024 Highlights of Key Lymphoma Data

0:18:00

Leukemia ASH 2024 Highlights - Menin Inhibitors, CPX 351 vs 7+3, Venetoclax Based Regimens

0:09:45

Dr Burke Pinpoints Top Trends from ASH 2024

0:02:03

Key takeaways in the R/R FL space from ASH 2024

0:15:36

Innovations in Hematology, ASH 2024 Highlights

0:22:19

Multiple Myeloma ASH 2024 Highlights with Dr. Robert Orlowski

0:10:45

EPCORE CLL-1: An Advance in Treating Relapsed/Refractory Chronic Lymphocytic Leukemia

0:01:44

CELESTIAL from ASH 2024: Sonrotoclax + Zanubrutinib vs Venetoclax + Obinutuzumab for TN CLL

0:15:20

Highlights from ASH: Canadian Perspective on the ALPINE Trial in CLL

0:01:45

Key CML updates from ASH 2024

0:06:46

AMPLIFY Updates from ASH 2024: Acal + Ven +/- Obin vs. Chemo-I/O for Newly Dx CLL

0:01:21

Hodgkin lymphoma highlights from ASH 2023: nivo-AVD versus BV-AVD in patients with HL

0:00:58

What is your preferred BTK inhibitor in CLL?